High Blood Pressure Variability is an Additional Cardiovascular Risk Factor
Blood pressure (BP) is a highly variable physiological indicator. Most people have BP changes within 40-50 mmHg during the day. Various external factors (from the patient’s position during BP measurement to poor adherence to therapy and abuse of short-acting antihypertensive drugs) affect the assess...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2020-03-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2129 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227599081897984 |
|---|---|
| author | A. V. Rodionov |
| author_facet | A. V. Rodionov |
| author_sort | A. V. Rodionov |
| collection | DOAJ |
| description | Blood pressure (BP) is a highly variable physiological indicator. Most people have BP changes within 40-50 mmHg during the day. Various external factors (from the patient’s position during BP measurement to poor adherence to therapy and abuse of short-acting antihypertensive drugs) affect the assessed indicators. Evaluation of the average daily, intra-visit, as well as long-term ("from visit to visit") BP variability is used in clinical practice. In the past twenty years a number of major studies demonstrated that increased BP variability is an independent prognostic factor that increases the risk of cardiovascular complications. The largest meta-analysis of 41 studies showed that an increase in long-term BP variability was associated with 15% and 18% increase in total and cardiovascular mortality, respectively. According to the IDHOCO project, the threshold coefficient of variation for day-today variability is >11.0/12.8. Different groups of antihypertensive drugs have an uneven effect on BP variability. Consistent data from ASCOT-BPLA, X-CELLENT and ACCOMPLISH studies indicate that among the main groups of antihypertensive drugs, calcium antagonists, mainly amlodipine, have the greatest potential for the variability reduction. A decrease in BP variability, as shown in a post-hoc analysis of CAMELOT and PREVENT studies, has a positive effect on the incidence of major adverse cardiac events (MACE). Thus, the BP variability is an important indicator that reflects the prognosis in hypertensive patients. BP variability reduction can be considered as one of the independent goals of therapy. Calcium antagonists can be considered as first-line drugs for patients with high BP variability. |
| format | Article |
| id | doaj-art-b33207b9a5bf4f44acfe22a72cfad296 |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2020-03-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-b33207b9a5bf4f44acfe22a72cfad2962025-08-23T10:00:32ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532020-03-01161949810.20996/1819-6446-2020-02-021705High Blood Pressure Variability is an Additional Cardiovascular Risk FactorA. V. Rodionov0I.M. Sechenov First Moscow State Medical University (Sechenov University)Blood pressure (BP) is a highly variable physiological indicator. Most people have BP changes within 40-50 mmHg during the day. Various external factors (from the patient’s position during BP measurement to poor adherence to therapy and abuse of short-acting antihypertensive drugs) affect the assessed indicators. Evaluation of the average daily, intra-visit, as well as long-term ("from visit to visit") BP variability is used in clinical practice. In the past twenty years a number of major studies demonstrated that increased BP variability is an independent prognostic factor that increases the risk of cardiovascular complications. The largest meta-analysis of 41 studies showed that an increase in long-term BP variability was associated with 15% and 18% increase in total and cardiovascular mortality, respectively. According to the IDHOCO project, the threshold coefficient of variation for day-today variability is >11.0/12.8. Different groups of antihypertensive drugs have an uneven effect on BP variability. Consistent data from ASCOT-BPLA, X-CELLENT and ACCOMPLISH studies indicate that among the main groups of antihypertensive drugs, calcium antagonists, mainly amlodipine, have the greatest potential for the variability reduction. A decrease in BP variability, as shown in a post-hoc analysis of CAMELOT and PREVENT studies, has a positive effect on the incidence of major adverse cardiac events (MACE). Thus, the BP variability is an important indicator that reflects the prognosis in hypertensive patients. BP variability reduction can be considered as one of the independent goals of therapy. Calcium antagonists can be considered as first-line drugs for patients with high BP variability.https://www.rpcardio.online/jour/article/view/2129arterial hypertensionblood pressure variabilitypharmacotherapycalcium channel blockers |
| spellingShingle | A. V. Rodionov High Blood Pressure Variability is an Additional Cardiovascular Risk Factor Рациональная фармакотерапия в кардиологии arterial hypertension blood pressure variability pharmacotherapy calcium channel blockers |
| title | High Blood Pressure Variability is an Additional Cardiovascular Risk Factor |
| title_full | High Blood Pressure Variability is an Additional Cardiovascular Risk Factor |
| title_fullStr | High Blood Pressure Variability is an Additional Cardiovascular Risk Factor |
| title_full_unstemmed | High Blood Pressure Variability is an Additional Cardiovascular Risk Factor |
| title_short | High Blood Pressure Variability is an Additional Cardiovascular Risk Factor |
| title_sort | high blood pressure variability is an additional cardiovascular risk factor |
| topic | arterial hypertension blood pressure variability pharmacotherapy calcium channel blockers |
| url | https://www.rpcardio.online/jour/article/view/2129 |
| work_keys_str_mv | AT avrodionov highbloodpressurevariabilityisanadditionalcardiovascularriskfactor |